Calculated plasma volume status and prognosis in chronic heart failure
Open Access
- 3 December 2014
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 17 (1), 35-43
- https://doi.org/10.1002/ejhf.193
Abstract
Aims Plasma volume (PV) expansion hallmarks worsening chronic heart failure (CHF) but no non-invasive means of quantifying volume status exists. Because weight and haematocrit are related to PV, they can be used to calculate relative PV status (PVS). We tested the validity and prognostic utility of calculated PVS in CHF patients. Methods and results First, we evaluated the agreement between calculated actual PV (aPV) and aPV levels measured using 125Iodine-human serum albumin. Second, we derived PVS as: [(calculated aPV – ideal PV)/ideal PV] × 100%. Third, we assessed the prognostic implications of PVS in 5002 patients from the Valsartan in Heart Failure Trial (Val-HeFT), and validated this in another 246 routine CHF outpatients. On analysis, calculated and measured aPV values correlated significantly in 119 normal subjects and 30 CHF patients. In the Val-HeFT cohort, mean (+SD) PVS was –9 ± 8% and related to volume biomarkers such as brain natriuretic peptide (BNP). Over 2 years, 977 (20%) patients died. Plasma volume status was associated with death and first morbid events in a ‘J-shaped’ fashion with the highest risk seen with a PVS > –4%. Stratification into PVS quartiles confirmed that a PVS > –4% was associated with increased mortality (unadjusted hazard ratio 1.65, 95% confidence interval 1.44–1.88, χ2 = 54, P < 0.001) even after adjusting for 22 variables, including brain natriuretic peptide. These results were mirrored in the validation cohort. Conclusions Relative PVS calculated from simple clinical indices reflects the degree to which patients have deviated from their ideal PV and independently relates to outcomes. The utility of PVS-driven CHF management needs further evaluation.Keywords
This publication has 26 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012European Journal of Heart Failure, 2012
- Aliskiren, ALTITUDE, and the implications for ATMOSPHEREEuropean Journal of Heart Failure, 2012
- Intrathoracic Impedance vs Daily Weight Monitoring for Predicting Worsening Heart Failure Events: Results of the Fluid Accumulation Status Trial (FAST)Congestive Heart Failure, 2011
- Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and SurvivalCirculation, 2010
- Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial)Journal of the American College of Cardiology, 2008
- Patterns of Weight Change Preceding Hospitalization for Heart FailureCirculation, 2007
- Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failureAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2006
- Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomesThe American Journal of Cardiology, 2004
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureThe New England Journal of Medicine, 2001
- The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failureJournal of the American College of Cardiology, 1992